What is ALX Oncology?
Headquartered in South San Francisco, ALX Oncology is dedicated to transforming the treatment landscape for cancer patients through the development of next-generation immuno-oncology agents. The company's core asset, Evorpacept, is a sophisticated CD47 blocking therapeutic biologic designed to enhance the innate and adaptive immune response against solid tumors. By leveraging a robust network of collaborative agreements with industry leaders and academic institutions—including Jazz Pharmaceuticals, Sanofi, and MD Anderson Cancer Center—ALX Oncology is effectively de-risking its clinical pipeline. The firm's strategic focus on combination therapies, such as the ASPEN clinical study series, positions it at the forefront of precision medicine, targeting significant unmet needs in gastric, urothelial, and head and neck squamous cell carcinomas.
How much funding has ALX Oncology raised?
ALX Oncology has raised a total of $576.7M across 5 funding rounds:
Series A
$36M
Series C
$105M
Stock Offering
$185.7M
Debt
$100M
Unspecified
$150M
Series A (2015): $36M with participation from the Longevity Fund, Stanford University, and Lightstone Ventures
Series C (2020): $105M led by Lightstone Ventures, Janus Henderson, Foresite Capital, HBM Healthcare Investments AG, BVF Partners L.P., Vivo Capital LLC, venBio Partners LLC, Logos Capital LLC, and Cormorant Asset Management , LLC
Stock Issuance/Offering (2020): $185.7M, investors not publicly disclosed
Debt (2022): $100M featuring Silicon Valley Bank and Oxford Finance
Unspecified (2026): $150M, investors not publicly disclosed
Key Investors in ALX Oncology
Lightstone Ventures
Lightstone Ventures backs founders turning cutting edge science into new therapies and medical technologies, providing capital and deep industry insight to transform lab ideas into clinical treatments.
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data to address significant unmet medical needs.
HBM Healthcare Investments AG
HBM Healthcare Investments is a publicly traded firm focused on the global healthcare sector, capitalizing on growth opportunities driven by medical advancements and the demand for innovative therapies.
What's next for ALX Oncology?
With the recent strategic investment, ALX Oncology is well-positioned to advance its clinical-stage assets through pivotal data readouts and expanded trial enrollment. The company's forward-looking strategy emphasizes the optimization of Evorpacept in combination with established anti-cancer agents, aiming to establish new standards of care in refractory oncology settings. Furthermore, the continued development of ALTA-002, in partnership with Tallac Therapeutics, highlights the firm's commitment to diversifying its therapeutic modalities. As the company moves deeper into its clinical roadmap, the focus will remain on achieving regulatory milestones and fostering strategic partnerships that validate its platform's efficacy, ultimately driving long-term value for stakeholders and improving patient outcomes in the global oncology market.
See full ALX Oncology company page
